logo
logo
Nyxoah S.A.

Nyxoah S.A.

NASDAQ•NYXH
CEO: Mr. Robert Taub MBA
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 2021-04-28
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
連絡先情報
Rue Edouard Belin 12, Mont-Saint-Guibert, 1435, Belgium
32-10-22-23-55
www.nyxoah.com
時価総額
$163.57M
PER (TTM)
-1.6
66.1
配当利回り
--
52週高値
$11.87
52週安値
$4.10
52週レンジ
4%
順位56Top 81.7%
2.5
F-Score
改良版 Piotroski 分析
8年ファンダメンタル
弱い • 2.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2018-2025

財務ダッシュボード

Q3 2025 データ

売上高

$2.31M+55.77%
直近4四半期の推移

EPS

-$0.74+26.00%
直近4四半期の推移

フリーCF

-$23.97M+44.28%
直近4四半期の推移

2024 Annual 決算ハイライト

主なハイライト

Revenue and Gross Profit Growth Revenue reached €4.5M, up 4%. Gross Profit increased 10% to €2.97M, driven by European commercialization.
DREAM Trial Primary Endpoint Met Pivotal DREAM trial met primary endpoints March 2024. PMA submission finalized, targeting US market availability Q1 2025.
Strengthened Cash Position Cash and equivalents totaled €34.2M as of December 31, 2024, providing at least 12 months funding runway.

リスク要因

Internal Control Material Weaknesses Material weaknesses persist in internal controls related to insufficient accounting personnel and supervisory oversight.
Widening Operating Loss Operating loss widened 30% to €58.8M in 2024 due to increased R&D and SG&A expenses.
US Regulatory Approval Uncertainty US FDA marketing authorization timeline remains uncertain despite PMA submission completion; delays could impact growth.
Need for Future Capital Continued operating losses necessitate future capital raises, which may not be available on commercially favorable terms.

見通し

US Market Launch Anticipated Expect FDA marketing authorization and commercial availability in the United States during the first quarter of 2025.
Expanding Commercial Footprint Continue investing in European sales teams and building US commercial organization capacity in anticipation of launch.
Product Pipeline Investment Investing in next-generation Genio 3.1 system development and expanding indications through ongoing clinical trials.
Focus on Favorable Reimbursement Pursuing favorable reimbursement coverage in key European markets to drive broad acceptance and adoption of the system.

同業比較

売上高 (TTM)

Inogen, Inc.INGN
$347.03M
+4.7%
Neuronetics, Inc.STIM
$129.87M
+78.6%
Genfit S.A.GNFT
$126.71M
+9.8%

粗利益率 (最新四半期)

Genfit S.A.GNFT
100.0%
+0.0pp
Sangamo Therapeutics, Inc.SGMO
100.0%
+0.0pp
Invivyd, Inc.IVVD
91.7%
+0.4pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
TRDA$412.77M-4.3-26.4%12.7%
GNFT$398.37M-9.2-63.7%64.1%
CATX$373.18M-3.5-39.1%1.1%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
19.6%
高成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月12日
|
EPS:-$0.65
|
売上高:-
財務レポート
財務データ
全年度

  • Form 20-F - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月20日|
    売上高: $4.89M+4.0%
    |
    EPS: $-1.96-16.8%
    予想を下回る

  • Form 20-F - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月20日|
    売上高: $4.70M+41.0%
    |
    EPS: $-1.68-28.1%
    予想を下回る

  • Form 20-F - FY 2022

    会計期末: 2022年12月31日|提出日: 2023年3月22日|
    売上高: $4.70M+262.0%
    |
    EPS: $-1.68-4.3%
    予想を下回る

  • Form 20-F - FY 2021

    会計期末: 2021年12月31日|提出日: 2022年3月24日|
    売上高: $4.70M+1134.8%
    |
    EPS: $-1.68-70.6%
    予想を下回る